FutureWorld (OTCMKTS:FWDG) and Epizyme (NASDAQ:EPZM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.
This table compares FutureWorld and Epizyme’s net margins, return on equity and return on assets.
This table compares FutureWorld and Epizyme’s top-line revenue, earnings per share and valuation.
FutureWorld has higher earnings, but lower revenue than Epizyme.
Institutional Insider Ownership
73.8% of Epizyme shares are held by institutional investors. 21.5% of Epizyme shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
FutureWorld has a beta of 1.25, indicating that its stock price is 25% more volatile than the SP 500. Comparatively, Epizyme has a beta of 3,